A novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6) has been reported by scientists at the University of Texas MD Anderson Cancer Center.
In this GEN webinar, sponsored by Precision NanoSystems, our distinguished speaker, Dr. Ethan Settembre, will introduce us to the intricacies of saRNA and how it elicits immune responses. Moreover, he will describe the differences between saRNA vs. mRNA, how saRNA can be applied to generate influenza and COVID-19 vaccines, and why it may represent the future of RNA therapeutic development.
Single-cell RNA sequencing enables the gene expression of each individual cell to be comprehensively analyzed. This approach has been carried out on the plaque that causes carotid arteries to harden (arteriosclerosis), but no such studies have been conducted on carotid plaque due to its being difficult to obtain a sample. The formation of artery-hardening plaque has been strongly linked to inflammation.
A COVID-19 vaccine, designed to be taken as a pill, has been shown not only to protect the host but also to decrease the airborne spread of the virus to close contacts. The findings, from experiments done in a hamster model that mimics human exposures, demonstrate that mucosal immunization is a viable strategy to decrease the spread of SARS-CoV-2 through airborne transmission.
Stay at the forefront of the week’s champions and runners-up among publicly traded biotech companies and the reasons behind the ups or downs of...
A new mouse study by researchers at UT Southwestern reveals that a subset of cancer-associated fibroblasts may be a potential therapeutic target in pancreatic cancer. The researchers believe by targeting antigen-presenting cancer-associated fibroblasts, they may one day be able to enhance the activity of immune therapy in pancreatic cancer patients.
Cytovia’s parent Cytovia Holdings has disclosed plans to go public by merging with Isleworth Healthcare Acquisition Corp., a SPAC based in St. Petersburg, FL, in a deal expected to be completed in the third quarter. Upon completion, Isleworth will be renamed Cytovia Therapeutics, and continue researching, developing, and manufacturing therapies based on its complementary natural killer (NK) cell and NK engager antibody platforms.
Matica Bio provides viral vector GMP manufacturing services for cell and gene therapies, vaccines, oncolytic vectors, and other advanced therapy products. Its GMP facility in College Station, TX, is designed for the rapid development, scaleup, and production of viral vectors and cell therapy products for clinical supply. Matica Bio offers process development, GMP production, product release, and stability assessment together with quality oversight and regulatory guidance.
Researchers at Weill Cornell Medicine and the Dana Farber Cancer Institute report that a protein called CDC7, that has been known to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1. Their findings may lead to new cancer therapies.
It's not often that a failed clinical trial leads to a scientific breakthrough. But when researchers in the U.S. and the U.K. carried out genomic evaluation of samples from a Phase II immunotherapy trial in which more than half of patients had to stop treatment due to immune-related side effects, they uncovered important clues as to the cause, and found through subsequent experiments in mouse models that an intermittent dosing strategy may be safer.